NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Cabozantinib for previously treated advanced renal cell carcinoma - NICE TAG TA463

Cabozantinib for previously treated advanced renal cell carcinoma - NICE TAG TA463

1.1Cabozantinib is recommended, within its marketing authorisation, as an option for treating advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)-targeted therapy, only if the company provides cabozantinib with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta463

Site by Devopa
© Copyright 2020 NHS. All rights reserved.